Management of a Type I Hypersensitivity Reaction to IV Etoposide in a Woman with a Yolk Sac Tumor: A Case Report

Management of a Type I Hypersensitivity Reaction to IV Etoposide in a Woman with a Yolk Sac Tumor: A Case Report

Type I hypersensitivity reactions to intravenous administration of etoposide are extremely rare. Etoposide is an essential component of several chemotherapy regimens used in gynecologic oncology, and discontinuation of this drug during a co...

Full description

Bibliographic Details
Main Authors: David Starks, Deborah Prinz, Amy Armstrong, Lindsay Means, Steven Waggoner, Robert DeBernardo
Format: Article
Language:English
Published: Hindawi Limited 2011-01-01
Series:Case Reports in Obstetrics and Gynecology
Online Access:http://dx.doi.org/10.1155/2011/837160
id doaj-839d815fafb343ad991b7b632b56fe4a
record_format Article
spelling doaj-839d815fafb343ad991b7b632b56fe4a2020-11-25T01:41:03ZengHindawi LimitedCase Reports in Obstetrics and Gynecology2090-66842090-66922011-01-01201110.1155/2011/837160837160Management of a Type I Hypersensitivity Reaction to IV Etoposide in a Woman with a Yolk Sac Tumor: A Case ReportDavid Starks0Deborah Prinz1Amy Armstrong2Lindsay Means3Steven Waggoner4Robert DeBernardo5MacDonald Women's Hospital, University Hospitals Case Medical Center, Cleveland, OH 44106, USAWomen's Health Institute, The Cleveland Clinic Foundation, Cleveland, OH 44195, USAWomen's Health Institute, The Cleveland Clinic Foundation, Cleveland, OH 44195, USAWomen's Health Institute, The Cleveland Clinic Foundation, Cleveland, OH 44195, USAWomen's Health Institute, The Cleveland Clinic Foundation, Cleveland, OH 44195, USAWomen's Health Institute, The Cleveland Clinic Foundation, Cleveland, OH 44195, USAType I hypersensitivity reactions to intravenous administration of etoposide are extremely rare. Etoposide is an essential component of several chemotherapy regimens used in gynecologic oncology, and discontinuation of this drug during a course of treatment should only be due to severe patient intolerance. We report the successful use of intravenous etoposide phosphate as a substitute drug in a patient with a yolk sac tumor who manifested a Type I hypersensitivity to intravenous etoposide. The patient ultimately completed all 4 cycles of bleomycin, etoposide, cisplatin (BEP) using etoposide phosphate as a substitute drug.http://dx.doi.org/10.1155/2011/837160
collection DOAJ
language English
format Article
sources DOAJ
author David Starks
Deborah Prinz
Amy Armstrong
Lindsay Means
Steven Waggoner
Robert DeBernardo
spellingShingle David Starks
Deborah Prinz
Amy Armstrong
Lindsay Means
Steven Waggoner
Robert DeBernardo
Management of a Type I Hypersensitivity Reaction to IV Etoposide in a Woman with a Yolk Sac Tumor: A Case Report
Case Reports in Obstetrics and Gynecology
author_facet David Starks
Deborah Prinz
Amy Armstrong
Lindsay Means
Steven Waggoner
Robert DeBernardo
author_sort David Starks
title Management of a Type I Hypersensitivity Reaction to IV Etoposide in a Woman with a Yolk Sac Tumor: A Case Report
title_short Management of a Type I Hypersensitivity Reaction to IV Etoposide in a Woman with a Yolk Sac Tumor: A Case Report
title_full Management of a Type I Hypersensitivity Reaction to IV Etoposide in a Woman with a Yolk Sac Tumor: A Case Report
title_fullStr Management of a Type I Hypersensitivity Reaction to IV Etoposide in a Woman with a Yolk Sac Tumor: A Case Report
title_full_unstemmed Management of a Type I Hypersensitivity Reaction to IV Etoposide in a Woman with a Yolk Sac Tumor: A Case Report
title_sort management of a type i hypersensitivity reaction to iv etoposide in a woman with a yolk sac tumor: a case report
publisher Hindawi Limited
series Case Reports in Obstetrics and Gynecology
issn 2090-6684
2090-6692
publishDate 2011-01-01
description Type I hypersensitivity reactions to intravenous administration of etoposide are extremely rare. Etoposide is an essential component of several chemotherapy regimens used in gynecologic oncology, and discontinuation of this drug during a course of treatment should only be due to severe patient intolerance. We report the successful use of intravenous etoposide phosphate as a substitute drug in a patient with a yolk sac tumor who manifested a Type I hypersensitivity to intravenous etoposide. The patient ultimately completed all 4 cycles of bleomycin, etoposide, cisplatin (BEP) using etoposide phosphate as a substitute drug.
url http://dx.doi.org/10.1155/2011/837160
work_keys_str_mv AT davidstarks managementofatypeihypersensitivityreactiontoivetoposideinawomanwithayolksactumoracasereport
AT deborahprinz managementofatypeihypersensitivityreactiontoivetoposideinawomanwithayolksactumoracasereport
AT amyarmstrong managementofatypeihypersensitivityreactiontoivetoposideinawomanwithayolksactumoracasereport
AT lindsaymeans managementofatypeihypersensitivityreactiontoivetoposideinawomanwithayolksactumoracasereport
AT stevenwaggoner managementofatypeihypersensitivityreactiontoivetoposideinawomanwithayolksactumoracasereport
AT robertdebernardo managementofatypeihypersensitivityreactiontoivetoposideinawomanwithayolksactumoracasereport
_version_ 1725042775719673856

Similar Items